- Cosmo reports strong half-year 2022 financial results delivering record revenues and reaffirms 2022 full-year guidance
- Cosmo and 3SBio Announce Signing of License Agreement for Winlevi® in China
- Cosmo and Sun Pharma Announce Territory Expansion of License and Supply Agreements for WINLEVI® to include Japan, Australia, New Zealand, Brazil, Mexico and Russia
Cosmo Pharmaceuticals NV (COPN:SWX) closed at 46.15, 9.10% above its 52-week low of 42.30, set on Jun 16, 2022.
42.30Jun 16 202280.70Sep 30 2021
Markit short selling activity
|Market cap||807.45m CHF|
|EPS (TTM)||1.80 |
|Annual div (ADY)||0.9741 |
|Annual div yield (ADY)||2.11%|
|Div ex-date||Jun 01 2022|
|Div pay-date||Jun 03 2022|
Data delayed at least 15 minutes, as of Sep 30 2022 16:31 BST.